CD19 and neoplasm: Blinatumomab anti-tumor activity is accomplished by the formation of a synapse between the T-cell and the tumor cell independently of MHC, by upregulation of cell adhesion molecules, production of cytolytic proteins, the release of inflammatory cytokines, and proliferation of T-cells, which result in directed CD19+ cell lysis.